HEPANTIVIR CLINICAL TRIA
Not Applicable
- Conditions
- HEPATITIS
- Registration Number
- PACTR201507001055177
- Lead Sponsor
- BOLAR PHARMACEUTICALS LTD
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
Fifty consecutive and consenting patients being managed by gastroenterology unitwith clinical and biochemical features as well as serological evidence of chronic hepatitis B infection and who meet the study criteria- 18 years and above, HBsAg positive with elevated serum ALT, Serum HBV DNA > 2000iu/ml
Exclusion Criteria
No consent, presence of underlying liver malignancy, presence of co-morbidities eg end-organ failure
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method improvement in symptoms, laboratory measurement including transaminase and HBV load as well as any adverse event will be compared between the treatment arm and tenofovir using chi sqaure test.
- Secondary Outcome Measures
Name Time Method Absence of HBV DNA